Tools for Practice

#332 A Jab for Your CAD: Influenza vaccination for the prevention of cardiovascular events

Does influenza vaccination reduce the risk of cardiovascular events?

For every 100 patients vaccinated for influenza within about one month after an acute coronary syndrome, there will be 2 fewer cardiovascular events and 2 fewer deaths at one year compared to placebo. The impact of influenza vaccination in primary cardiovascular prevention and other cardiovascular conditions is less clear.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

Join Now

Already a CFPCLearn Member? Log in

  • Five meta-analyses1-5 compared the effect of influenza vaccination to placebo/no vaccination on cardiovascular events (5-8 randomized controlled trials [RCTs], 4,211-12,029 patients, follow-up 1.5-12 months). Focusing on the most complete (results statistically significant unless otherwise stated):
  • Secondary prevention:
    • Influenza vaccination reduced the risk of all-cause mortality (relative risk reduction [RRR] 42%) and cardiovascular events (RRR 37%).1
      • Largest, highest-quality, multi-country (mostly European) RCT6 compared one-time influenza vaccination to placebo in 2,532 participants ≤3 days after myocardial infarction. At 1 year:
        • Death: 2.9% versus 4.9% with placebo.
        • Cardiovascular events (death, myocardial infarction, stent thrombosis): 5.3% versus 7.2% with placebo.
        • Local injection site reactions: ~5% absolute increase.
      • Limitations: Cardiovascular benefit only seen in patients within <2 months of acute coronary syndrome (unclear benefit in chronic coronary artery disease) in subgroup analysis.2
    • Other cardiovascular disease:7
      • Influenza vaccine did not reduce death or cardiovascular events in 2-year RCT of 5,129 patients with heart failure when compared to placebo but reduced overall hospitalization (15% versus 18% with placebo).
    • Primary prevention:3
      • No difference in cardiovascular deaths based on 12 events in 2 RCTs.
      • No other cardiovascular events reported.
    • No difference in cardiovascular events between: Different vaccine types/dose;8 or timing (administration during myocardial infarction hospitalization or within 30 days of discharge).9
  • Recent respiratory tract infections/influenza are associated with increased risk of cardiovascular events.10-11
  • Guidelines recommend influenza vaccination for people with coronary disease.12
  • ~40% of Canadian adults with a chronic condition receive influenza vaccination each year.13
  • Influenza vaccine efficacy for secondary cardiovascular prevention is comparable to other preventive therapies in reducing recurrent cardiovascular events [examples: Acetylsalicylic acid and statins (RRR ~25%)].14,15

Latest Tools for Practice

#348 How to Slow the Flow III: Tranexamic acid for heavy menstrual bleeding (Free)

In premenopausal heavy menstrual bleeding due to benign etiology, does tranexamic acid (TXA) improve patient outcomes?
Read 0.25 credits available

#347 Chlorthali-D’OH!: What is the best thiazide diuretic for hypertension?

Which thiazide diuretic is best at reducing cardiovascular events in hypertension?
Read 0.25 credits available

#346 Stress Urinary Incontinence: Pelvic floor exercises or pessary? (Free)

How effective are pelvic floor exercises or pessaries for stress urinary incontinence?
Read 0.25 credits available

This content is certified for MainPro+ Credits, log in to access


  • Blair J. MacDonald PharmD
  • Michael R. Kolber BSc MD MSc CCFP
  • Ricky D Turgeon BSc (Pharm) ACPR PharmD

1. Diaz-Arocutipa C, Saucedo-Chinchay J, Mamas MA, Vicent L. Travel Med Infect Dis. 2022;47:102311.

2. Behrouzi B, Bhatt DL, Cannon CP, et al. JAMA Netw Open. 2022; 5:e228873.

3. Clar C, Oseni Z, Flowers N, et al. Cochrane Database Syst Rev. 2015; 5:CD005050.

4. Udell JA, Zawi R, Bhatt DL, et al. JAMA. 2013; 310(16):1711-20.

5. Jaiswal V, Ang SP, Yaqoob S, et al. Eur J Prev Cardiol. 2022; 00:1-12.

6. Fröbert O, Götberg M, Erlinge D, et al. Circulation. 2021; 144(18):1476-84.

7. Loeb M, Roy A, Dokainish H, et al. Lancet Glob Health. 2022; 10:e1835-44.

8. Vardeny O, Kim K, Udell JA, et al. JAMA. 2021;325(1):39-49.

9. Fonseca HAR, Furtado RHM, Zimerman A, et al. Eur Heart J. 2022;43:4378-88.

10. Smeeth L, Thomas SL, Hall AJ, et al. N Engl J Med. 2004;351:2611-8.

11. Barnes M, Heywood AE, Mahimbo A, et al. Heart. 2015;101:1738-47.

12. Fihn SD, Gardin JM, Abrams J, et al. Circulation. 2012;126:3097-137.

13. Public Health Agency of Canada. Available at: Accessed 2022 November 8.

14. Antithrombotic Trialists’ Collaboration. Lancet. 2009;373:1849-60.

15. Wilt TJ, Bloomfield HE, MacDonald R, et al. Arch Intern Med. 2004;164:1427-36.

Authors do not have any conflicts of interest to declare.